Why the study?
Does the genetic polymorphism of CYP2D6 and ADRB1 affect the hypotensive and antichronotropic response to betaxolol in patients with essential hypertension?
Observational (n=81)
Does the genetic polymorphism of CYP2D6 and ADRB1 affect the hypotensive and antichronotropic response to betaxolol in patients with essential hypertension?
Absolute Event Rate: -21% vs -5.2%
p-value: p=0.001
The hypotensive and antichronotropic effects of betaxolol in patients with essential hypertension are significantly influenced by CYP2D6 gene polymorphisms, with Pro34 allele carriers showing greater sensitivity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zateyshchikov et al. (2007) conducted an observational in essential hypertension (n=81). CYP2D6 Pro34Ser polymorphism (Pro allele) vs. Ser/Ser genotype was evaluated on Decline of mean daytime systolic blood pressure (p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: